phox -gp91 phox interaction (Ad-gp91ds). Common carotid arteries (CCAs) from male Sprague-Dawley rats were transfected with Ad-control, Ad-p67dn, or Ad-gp91ds in pluronic gel. After 2 days, a 2-F (Fogarty) catheter was used to injure CCAs in vivo. After 14 days, CCAs were perfusion-fixed and analyzed. In 13 experiments, digital morphometry suggested a reduction of neointimal hyperplasia with Ad-p67dn compared with Ad-control; however, the reduction did not reach statistical significance (P ϭ 0.058). In contrast, a significant reduction was achieved with Adgp91ds (P ϭ 0.006). No changes in medial area or remodeling were observed with either treatment. Moreover, adventitial fibroblast proliferation in vitro was inhibited by Ad-gp91ds but not by Ad-p67dn, despite confirmation that Ad-p67dn inhibits NADPH oxidase in fibroblasts. These data appear to suggest that a multicomponent vascular NADPH oxidase plays a role in neointimal hyperplasia. However, inhibition of p47 phox may be more effective than inhibition of p67 phox at attenuating neointimal growth.
activity would attenuate angioplasty-induced hyperplasia. To test this hypothesis, we treated the adventitia of carotid arteries with a control adenovirus (Ad-control), a virus expressing dominant-negative p67 phox (Ad-p67dn), or a virus expressing a competitive peptide (gp91ds) targeting the p47 phox -gp91 phox interaction (Ad-gp91ds). Common carotid arteries (CCAs) from male Sprague-Dawley rats were transfected with Ad-control, Ad-p67dn, or Ad-gp91ds in pluronic gel. After 2 days, a 2-F (Fogarty) catheter was used to injure CCAs in vivo. After 14 days, CCAs were perfusion-fixed and analyzed. In 13 experiments, digital morphometry suggested a reduction of neointimal hyperplasia with Ad-p67dn compared with Ad-control; however, the reduction did not reach statistical significance (P ϭ 0.058). In contrast, a significant reduction was achieved with Adgp91ds (P ϭ 0.006). No changes in medial area or remodeling were observed with either treatment. Moreover, adventitial fibroblast proliferation in vitro was inhibited by Ad-gp91ds but not by Ad-p67dn, despite confirmation that Ad-p67dn inhibits NADPH oxidase in fibroblasts. These data appear to suggest that a multicomponent vascular NADPH oxidase plays a role in neointimal hyperplasia. However, inhibition of p47 phox may be more effective than inhibition of p67 phox at attenuating neointimal growth.
NADPH oxidase; p47 phox ; adventitia; restenosis NEOINTIMAL HYPERPLASIA is a major response to vascular injury (33) . Proliferation and migration of vascular smooth muscle cells (VSMCs) and, more recently, fibroblasts have been implicated in narrowing of the arterial lumen in response to injury, mimicking one of the hallmark characteristics of atherosclerosis (6, 32) . Smooth muscle cell migration and proliferation are involved in narrowing of the arterial lumen in response to injury and atherosclerosis, a process promoted by protooncogenes (34) and various growth factors (11, 19) . Recent studies have implicated superoxide anion (O 2 Ϫ ) derived from NADPH oxidase in vascular cell proliferation and neointimal growth (17, 37) , and processes involving reactive oxygen species (ROS) have been included in a number of growth-related signaling pathways (14) .
NADPH oxidase is a well-characterized ROS-generating system that catalyzes the one-electron reduction of O 2 to O 2 Ϫ , a precursor of a variety of other ROS. The classical phagocyte NADPH oxidase is known to be a multicomponent enzyme complex that includes the two membrane-spanning polypeptide subunits p22 phox and anchoring component gp91 phox , which are associated with the plasma membrane cytoskeleton (and together comprise flavocytochrome b 558 ), along with three cytoplasmic polypeptide subunits, p40
phox , p47 phox , and p67 phox (8, 43) . The cytosolic guanine nucleotide-binding protein p21 rac , a member of the Ras family of proteins, is required for oxidase activation (20) . Exposure of the cell to agonists induces interaction of cytosolic and membrane-associated components and activates the dormant oxidase (8) . Numerous studies have suggested a similar process of oxidase activation in the vasculature (16, 23, 26, 29, 43) .
Recently, NADPH oxidases in VSMCs and adventitial fibroblasts have been implicated in the proliferation and migration of cells from the vascular wall to the neointima (13, 18) . VSMCs in large arteries express p22 phox , p47 phox , and homologs of gp91 phox but do not appear to express p67 phox (21, 22, 36) . In contrast, we reported that the vascular adventitia expresses four major components of the oxidase and showed that classical p67 phox is involved in adventitial fibroblast O 2 Ϫ production (27, 40) . In smooth muscle cells and adventitial fibroblasts, critical components of NADPH oxidase are upregulated in response to vascular injury and atherosclerosis, and ROS derived from NADPH oxidase appear to be involved in cell proliferation and migration (2, 38) . We recently reported that delivery of a peptide targeting the interaction of p47 phox and gp91 phox (gp91ds) attenuates neointimal hyperplasia in vivo (18) . Thus we postulated that therapies targeting another essential component of the NADPH oxidase system, p67
phox , would prove useful in treating vascular injury. Moreover, in light of the growing interest in migrating adventitial fibroblasts playing an important role in neointimal hyperplasia, we examined the influence of p67 phox targeting on fibroblast proliferation in vitro.
In this study, we examined for the first time the ability of dominant-negative p67 phox (p67dn) to attenuate neointimal hyperplasia in response to balloon angioplasty and compared it with the effects of gp91ds. Focusing on the ability of adven-titial fibroblasts to participate in this response, we also compared the dose-dependent effects of each inhibitor on fibroblast proliferation in vitro. Our data suggest that p67dn attenuates angioplasty-induced increases in vascular neointima formation, but not to the same degree as gp91ds. Interestingly, p67dn had no effect on adventitial fibroblast proliferation in vitro, whereas gp91ds inhibited proliferation. These data appear to suggest that p47 phox plays a greater role in adventitial fibroblast proliferation and neointimal hyperplasia than p67 phox .
MATERIALS AND METHODS

Viral Oxidase Inhibitory Constructs
Ad-gp91ds. We designed a bicistronic adenoviral expression vector, Ad-PDGF ␤R-gp91ds-IRES-eGFP (Ad-gp91ds) to coexpress gp91ds inhibitory peptide and enhanced green fluorescent protein (eGFP) under the control of the platelet-derived growth factor-␤ receptor (PDGF ␤R). The pPDGF␤R-luciferase plasmid (3) was generously provided by Dr. K. Funa (Göteborg University, Göteborg, Sweden). A 1,468-bp portion of the pPDGF ␤R-luciferase plasmid was removed by Sac I digestion (3) (PDGF␤R promoter sequence) and inserted into a replication-deficient human adenovirus serotype 5 (Ad5) vector. This 1,468-bp portion of the pPDGF ␤R-luciferase vector was placed upstream from a Kozac sequence (GCC-ACC-ATG), followed by the nucleotide sequence (TGC-TCG-ACA-AGG-ATT-CGA-AGA-CAA-CTG) encoding the gp91ds peptide, an internal ribosome entry site (IRES) sequence, a 719-bp sequence encoding eGFP, and a sequence for simian virus 40 pRep8 poly(A).
Ad-p67dn. Adenovirus expressing p67dn (Ad-p67dn) was constructed at the Myocardial Biology Unit, Boston University, by placement of a cytomegalovirus (CMV) promoter upstream from the transcript encoding p67dn (substitution of alanine for valine at amino acid 204) as described by Han et al. (15) .
Ad-control. Ad-CMV-eGFP (University of Iowa Gene Transfer Core) was used as a control. eGFP expression was under the control of the CMV promoter.
Animals and Viral Infection
Male Sprague-Dawley rats (10 -12 wk old, 300 -400 g; Charles River) were anesthetized with ketamine (80 mg/kg ip) and xylazine (7 mg/kg ip), and the neck was dissected to expose the common carotid artery (CCA) as well as the internal and external carotid arteries. Ad-control, Ad-p67dn, or Ad-gp91ds in 15% pluronic gel [Poloxamer 407 NF, BASF; 3.5 ϫ 10 8 plaque-forming units (pfu)/ml] was gently spread around the outside of the left CCA. The incision was closed and the animals were allowed to recover, with free access to water and food. All protocols were approved by the Institutional Animal Care and Use Committee of Henry Ford Hospital and are consistent with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
In Vivo Balloon Injury and Morphometric Analysis of Neointima Formation
At 2 days after viral infection, the animals were anesthetized and the incision was reopened. A 4-0 silk ligature was tied around the distal portion of the left external carotid artery, and another was passed around the proximal portion but not tied. A small transverse arteriotomy was made between the ligatures, and a 2-Fr (Fogarty) embolectomy catheter (Edwards Life Sciences) was passed through the left CCA into the thoracic aorta. The balloon was distended with 0.9% saline to increase CCA diameter by ϳ100% and withdrawn through the CCA to cause arterial injury. Distension and withdrawal were repeated five times. After CCA injury, the balloon catheter was removed and the proximal external carotid artery suture was tied. After the incision was closed, the animals were allowed to recover, with free access to water and food. After 14 days, the vessels were perfusion-fixed with 10 ml of PBS followed by 10% formaldehyde in PBS under pressure (ϳ120 mmHg). CCAs were harvested (with care taken not to disrupt the adventitia) and embedded in paraffin, and the middle third was serially cut into 6-m sections. Masson's trichrome staining (Sigma), performed following the manufacturer's instructions, revealed several layers of elastic laminae. Digital morphometric analysis was performed using image analysis software (Spot Diagnostics) by an examiner with no knowledge of the treatment group. When cross-sectional area was measured, medial area was determined by subtraction of the area defined by the internal elastic lamina (IEL) from the area defined by the external elastic lamina (EEL). Intimal area was determined by subtraction of the luminal area from the area defined by the IEL. We compared elastolysis visually at high magnification by examining whether the IEL and EEL were intact. Radial thicknesses of the neointima and media were measured at four points around the circumference and averaged. Myointimal proliferation of the injured carotid artery was expressed as the ratio of neointimal area and thickness to medial area and thickness, respectively. The circumferences of the IEL and EEL were measured to examine the remodeling response. Each section was examined several times, and the values were averaged.
Immunohistochemistry for Carotid Artery eGFP and p67 phox Expression
Monoclonal mouse anti-eGFP (Clontech) was used to detect eGFP expression, and monoclonal mouse anti-p67 phox (generously supplied by Dr. Mark Quinn) (7) was used to detect p67 phox expression. Sections were heated at 58°C for 2 h, deparaffinized and hydrated using standard techniques, and then boiled in 10 mM citric acid buffer for 10 min for antigen retrieval. The sections were incubated in 0.3% H 2O2 in 80% methanol for 30 min. Immunostaining was performed using a mouse IgG kit (Vector Laboratories). The sections were blocked with 10% normal horse serum for 30 min and then incubated overnight at 4°C with primary antibody (1:250 dilution for anti-eGFP and 1:20 dilution for anti-p67 phox in PBS containing 2% normal horse serum). Negative controls were incubated with the same concentration of matching IgG isotype (IgG 2a). Sections were incubated with biotinylated secondary antibody (1:400 dilution in PBS containing 2% normal horse serum) for 30 min and then with ABC reagent for 30 min (Vector). The reaction was visualized using diaminobenzidine tetrahydrochloride (Vector Laboratories). The sections were counterstained with hematoxylin (Sigma), and the slides were dehydrated with alcohol, cleared in xylene, and mounted.
Preparation of Rat Aortic Adventitial Fibroblasts
Aortic fibroblasts were prepared as described previously (27) . Briefly, aortas from anesthetized rats were removed using sterile techniques and placed in DMEM containing 100 U/ml penicillin and 100 g/ml streptomycin. Vessels were cleaned of perivascular adipose tissue and cut longitudinally, and the endothelium was scraped free. The tissue was incubated in DMEM containing 1 mg/ml collagenase and 0.125 mg/ml elastase for 10 -15 min at room temperature. Medial smooth muscle cells were peeled from the adventitia, which was then digested in DMEM containing 1 mg/ml collagenase and 0.125 mg/ml elastase for 4 h at 37°C. The resulting solution was centrifuged, and the pellet was resuspended in DMEM containing 20% fetal bovine serum (FBS) and then seeded onto 100-mm culture dishes. These cells were considered passage 0.
Comparison of the Effect of Ad-p67dn and Ad-gp91ds on Adventitial Fibroblast Proliferation
Fibroblasts at passage 7 were seeded in six-well plates (Corning) at a density of 50,000 cells/well and grown to 60% confluence. The cells were washed extensively with Hanks' balanced salt solution to ensure total removal of serum and placed in 0% FBS-DMEM for 20 h (quiescence). Ad-control, Ad-p67dn, or Ad-gp91ds was added to individual wells for the dose-response assay (3.5 ϫ 10 7 , 1.0 ϫ 10 8 , and 3.5 ϫ 10 8 pfu/ml) and allowed to transfect the cells for 4 h. The medium was removed, and 0% FBS-DMEM or 10% FBS-DMEM was added to the wells. The cells were harvested at 66 h and counted in a Coulter counter. Cell number for each treatment group was calculated as a percentage and compared with Ad-control-treated cells.
Effect of Ad-p67dn on Adventitial Fibroblast NADPH Oxidase Activity
Fibroblasts at passage 7 were seeded in 60-mm culture plates (Corning), grown to 60% confluence, and brought to quiescence, and Ad-control or Ad-p67dn (3.5 ϫ 10 8 pfu/ml) was added for 4 h. The medium was replaced with 0% FBS-DMEM for 72-96 h. Vehicle (0.01 N acetic acid in saline) or ANG II (10 Ϫ7 M) was added, and the plates were incubated at 37°C for 3 h. NADPH oxidase activity was measured as described previously (30) by comparison of ANG IIstimulated NADPH-dependent lucigenin (5 M) chemiluminescence in Ad-control with that in Ad-p67dn-transfected cells.
Statistical Analyses
Values are means Ϯ SE, with n indicating the number of experiments in vivo. Morphometric measurements were compared for differences between groups by one-way ANOVA. Body weight, IEL and EEL circumference, and cell proliferation were compared by ANOVA with repeated measures. To determine differences, pairwise testing was implemented using Hochberg's method to set the criteria for significance and adjust for multiple testing. NADPH oxidase activity was examined using Student's two-sample t-test.
RESULTS
Body Weight
Body weight rose over the course of the study in all treatment groups. However, we observed no difference in body weight among groups at the beginning or end of the study. Figure 1A shows eGFP in a cross section of the rat CCA treated with Ad-control. Staining was prominent in both adventitia and neointima. Figure 1B shows a negative control from the Ad-control group in which primary antibody for eGFP was replaced by IgG 2a . In Fig. 1C , eGFP staining in a CCA treated with Ad-gp91ds demonstrates substantially lighter staining, primarily in the adventitia. At higher magnification (Fig. 1D) , staining was associated primarily with fusiform adventitial fibroblasts. We also confirmed an effect of the p67dn construct by immunohistochemistry using monoclonal p67 phox (7) . As shown in Fig. 1 , E and F, reactivity for p67 phox is reduced in Ad-p67dn-treated (n ϭ 4) compared with Adcontrol-treated carotid arteries (n ϭ 5). A negative control, in which primary antibody was replaced with IgG 2a , showed no reactivity (not shown). These data are consistent with reduced expression of the wild-type protein. Alternatively, reduced specific binding of the antibody as a consequence of overexpressed mutated p67dn may have resulted in lower overall reactivity. In both cases, p67 phox activity would be reduced, resulting in lower ROS production. Figure 2 shows representative cross sections of injured CCAs transfected with Ad-gp91ds and Ad-p67dn vs. Adcontrol. At 14 days after injury, in the control group, growth in neointimal and medial areas was approximately equal (Fig.  2A) . Neointimal-to-medial area ratio appeared partially reduced in CCAs treated with Ad-p67dn (Fig. 2B) and markedly reduced in those treated with Ad-gp91ds (Fig. 2C) .
Transgene Expression by Adenoviral Constructs
Effect of Oxidase Inhibitor Constructs vs. Control Virus on Injury-Induced Changes in Neointimal Area in Carotid Artery
There appeared to be a substantial decrease in neointimalto-medial area ratio in CCAs treated with Ad-p67dn compared with adenoviral control, as changes closely approached statistical significance (45%, P ϭ 0.058, n ϭ 13 vs. 25). By comparison, gp91ds-expressing virus caused a statistically significant reduction in neointimal-to-medial area ratio (67%, P ϭ 0.006, n ϭ 13 vs. 25; Fig. 3B ). Digital morphometric analysis suggested that neointimal area was smaller in CCAs from Ad-p67dn than from Ad-control (39%), but the difference was not significant; in contrast, neointimal area was significantly decreased by Ad-gp91ds (64%; Fig. 3A) . Similarly, neointimal thickness appeared reduced, but comparisons between Adcontrol and Ad-p67dn did not reach statistical significance (49%); on the other hand, thickness was significantly lower in CCAs treated with Ad-gp91ds than in those treated with Ad-control (63%; Fig. 4A ). Similarly, neointimal-to-medial thickness ratios appeared lower in the Ad-p67dn group (45%) but did not reach significance, whereas mean thickness ratio was significantly lower in the gp91ds group (64%, P ϭ 0.015; Fig. 4B ). Overall, data analysis of all comparisons of Adcontrol vs. Ad-p67dn approached statistical significance, suggesting a reduction in neointimal growth. No difference in elastolysis was observed between groups (data not shown). Although there was an apparent trend toward increased luminal area in the gp91ds group, it did not vary significantly across treatment protocols (data not shown).
Effect of Oxidase Inhibitor Constructs vs. Control Virus on CCA Medial Area
Contrary to the changes in neointimal area, neither inhibitor construct had any effect on medial area. Digital quantification of medial area (Fig. 5A ) and medial thickness (Fig. 5B) did not vary across treatment groups.
Effect of Oxidase Inhibitor Constructs vs. Control Virus on Vessel Size
To examine whether either treatment had any effect on vessel size, we digitally determined IEL and EEL circumference. Figure 6 , A and B, suggests a slight trend toward larger IEL and EEL circumference in the p67dn and gp91ds groups than in the control group; however, these data did not reach significance.
Concentration-Response Effects of Adenoviral Oxidase Inhibitors on Adventitial Fibroblast Proliferation
To examine the ability of each construct to inhibit cell proliferation more thoroughly, we tested the effect of a range of concentrations of each virus on adventitial fibroblast proliferation in vitro. We did not observe an inhibitory effect of either virus on fibroblast proliferation at 42 h after 10% serum treatment at any concentration tested. However, we observed a 35% reduction in cell number at 66 h of serum treatment with 3.5 ϫ 10 8 pfu/ml Ad-gp91ds (Fig. 7) , the same concentration that proved effective in vivo. Interestingly, Ad-p67dn did not affect adventitial fibroblast proliferation at any concentration.
Effect of Ad-p67dn on Adventitial Fibroblast NADPH Oxidase Activity
We previously established that gp91ds inhibits whole vessel and adventitial fibroblast ROS production (9, 18, 25, 30) . Thus we examined whether Ad-p67dn inhibits fibroblast NADPH oxidase activity, despite its lack of effect on proliferation. Figure 8 shows that ANG II-stimulated NADPH oxidase activity in adventitial fibroblasts was inhibited by 47% by treatment with 3.5 ϫ 10 8 pfu/ml Ad-p67dn vs. Ad-control.
DISCUSSION
Our present findings suggest that a vascular cell oxidase resembling the classical phagocyte NADPH oxidase is critically involved in neointimal growth arising from balloon angioplasty in the rat. Our data suggest for the first time that p67 phox may be involved in perivascular activation of the oxidase, which precedes neointimal hyperplasia; however, targeting of the p47 phox -gp91
phox interaction appears to inhibit this process more effectively. We and others previously established the presence of four major components of classical NADPH oxidase, gp91
phox , p47 phox , and p67 phox , in the perivascular region of rabbit and rat vessels and showed that p67 phox is involved in adventitial fibroblast oxidase activity (26, 27, 41) . Our present findings are consistent with partial involvement of this component in the vascular migratory and hyperplastic response to injury, because blocking it with novel adenoviral constructs partially reduced neointimal growth. In- phox -gp91phox interaction (Ad-gp91ds) stained for eGFP. Magnification ϫ400. D: C at a higher magnification (ϫ1,000 terestingly, when we examined the effects of Ad-gp91ds vs. those of Ad-p67dn on adventitial fibroblast proliferation in vitro, we found that, although Ad-p67dn reduced NADPH oxidase activity, only Ad-gp91ds was able to reduce cell growth. Taken together, these data appear to suggest that a multicomponent NADPH oxidase is involved in the fundamental processes leading to balloon angioplasty-induced neointimal hyperplasia. However, the data also appear to suggest that adventitial p47
phox is more critical to neointimal hyperplasia than classical p67 phox , especially with regard to the contribution by vascular fibroblasts, and may suggest that a homolog of p67 phox is involved in this process. Immunohistochemistry for eGFP revealed that adenoviral constructs delivered the marker gene to the perivascular cells and neointima of the rat CCA. Because there are no available means of immunologically distinguishing endogenous p67 from p67dn (a 1-amino acid substitution from the endogenous form), we were unable to assess p67dn delivery directly. Thus, as a control, we chose a vector expressing eGFP under the direction of the same CMV promoter, allowing us to use eGFP to determine p67dn distribution. When we performed immunohistochemistry for p67 phox , we found a marked decrease in p67 phox reactivity in Ad-p67dn-vs. Ad-control-treated carotid arteries. These data are consistent with reduced expression of the wild-type p67
phox . Alternatively, our data may suggest reduced specific binding of the antibody to the overexpressed mutated p67dn, resulting in decreased reactivity under the stringency of the immunohistochemical assay. In either case, p67 phox activity would be reduced in the Ad-p67dn group, resulting in lower ROS production.
Expression of eGFP in CCAs infected with Ad-gp91ds seems to be localized primarily to adventitial fibroblasts but is expected to include other proliferating cells. Limited adventitial eGFP expression early after injury (1 day) is consistent with the presence of its fibroblast-active PDGF ␤R promoter, which has been reported to direct expression in cells of a proliferative phenotype (3) . In fact, in our recent report examining the mouse carotid artery, we showed that Ad-gp91ds caused the inhibitor to be expressed primarily in fibroblasts; however, a subpopulation of macrophage-like cells also appeared to express the inhibitor (25) .
Practically speaking, the lower overall eGFP expression in Ad-gp91ds vs. Ad-control raised the question of whether higher eGFP expression in the controls may have contributed artificially to heightened neointimal growth and thus enhanced the effect of the inhibitory construct. This does not appear to be the case, because neointimal size and neointimal-to-medial area ratios were lower in Ad-eGFP-treated CCAs than in non-virus-treated controls (18) .
Neointimal hyperplasia is characterized by VSMC proliferation and migration to the neointima during injury. Recent studies suggest that adventitial myofibroblasts derived from fibroblasts also proliferate and migrate to the site of injury (24, 42) . Because fibroblast proliferation is ROS dependent (17) , inhibition of ROS production in adventitial fibroblasts may be an important means of attenuating the direct contribution of fibroblasts to injury-and atherosclerosis-related hyperplasia. Perhaps more importantly, perivascular oxidases appear to have an indirect paracrine effect on the vascular wall via the release of tissue-permeant ROS such as H 2 O 2 , which can stimulate medial smooth muscle cells to undergo a change from the contractile to the proliferative and migratory phenotype (31) . Regardless of a direct or indirect effect on proliferation, adventitial NADPH oxidase is increasingly being seen as an early mediator in this response (9) . Our present findings are consistent with both a paracrine and a direct effect of fibroblast oxidase inhibition on vascular cell hyperplasia.
Several reports have shown an association between various forms of vascular NADPH oxidase and neointimal growth (28, 38) . Moreover, studies have clearly shown that phosphorylation and translocation of the classical cytosolic component p47 phox to the plasma membrane participate in the process of vascular NADPH oxidase activation (23, 29) . We recently confirmed that interaction between p47 phox and gp91 phox in NADPH oxidase is involved in the production of vascular O 2 Ϫ and neointimal growth by showing that gp91ds-tat (a novel peptide inhibitor of p47-gp91 interaction and precursor of Ad-gp91ds) inhibits stretch-induced O 2 Ϫ production and neointimal growth of the rat CCA (18) . We infused gp91ds-tat or vehicle control into rats for 2 days and then examined O 2 Ϫ after stretch. We observed a significant reduction in ROS and neointimal proliferation by gp91ds-tat (18); in subsequent studies, we demonstrated that the active sequence gp91ds was capable of markedly reducing whole vessel and fibroblast ROS levels (9, 25) and neointimal proliferation (9) .
In the present study, on the basis of substantial evidence showing that vascular NADPH oxidase is a complex system composed of at least five essential components (31), we compared the antihyperplastic effect of delivering Ad-gp91ds vs. Ad-p67dn to the adventitia. We and others showed that classical NADPH oxidase components gp91 phox , p47 phox , and p67 phox are present in the aortic adventitia of the rabbit and rat (27, 40) and postulated that adventitial oxidase plays a role in the promotion of neointimal growth (31) . For this reason, we examined the potential contribution of adventitial p67 phox per se to vascular neointimal growth compared with the p47 phox -gp91 phox interaction. We previously showed that p67 phox is involved in adventitial fibroblast NADPH oxidase activity (21, 22, 36) . However, consistent with a lesser role of adventitial Fig. 6 . Ad-gp91ds and Ad-p67dn have no effect on parameters of remodeling, i.e., internal elastic lamina (IEL) and external elastic lamina (EEL) circumference, in CCAs 14 days after balloon injury. Values are means Ϯ SE; n ϭ 25 (Ad-control) and 13 (Ad-p67dn and Ad-gp91ds). phox in stretch-induced neointimal growth, the present morphometric data suggest a reduction in neointimal growth in adventitially applied Ad-p67dn-treated CCAs compared with viral controls, as changes closely approached statistical significance (45%, P ϭ 0.058). On the other hand, Ad-gp91ds caused statistically significant inhibition compared with control (67%, P ϭ 0.001). These data indicate that adventitial p47 phox is critically involved in NADPH oxidase-mediated neointimal growth and suggest a role for classical p67 phox , particularly because gp91ds expression seemed more limited than p67dn expression (Fig. 1B vs. 1A) . Moreover, the lesser effect of Ad-p67dn may be attributed in part to the presence of the p67 phox homolog NOXA1 (12) . It is unclear whether NOXA1 is important for adventitial or medial NADPH oxidase activity. Because inhibitors of this homolog are unavailable, we are currently unable to address the contribution of NOXA1 relative to that of p67 phox . Because a number of previous studies suggested a role for migrating adventitial fibroblasts per se in neointimal hyperplasia (35), we compared the effectiveness of Ad-p67dn vs. Ad-gp91ds to reduce fibroblast proliferation in vitro. Interestingly, we observed no effect of Ad-p67dn over a range of concentrations, including the highest concentration that showed a partial effect in vivo. In contrast, Ad-gp91ds caused a 35% reduction in fibroblast proliferation (compared with a 67% reduction in neointimal hyperplasia in vivo). Indeed, the greater effect of these constructs in vivo is consistent with the expected participation of multiple cell types in neointimal hyperplasia. That is, the enhanced effect of both adenoviral constructs in vivo appears to suggest that ROS derived from adventitial cell types other than fibroblasts play an important role in vascular cell hyperplasia and migration in this model. It is also noteworthy that Ad-p67dn did not inhibit fibroblast proliferation, despite its ability to decrease NADPH oxidase activity. Thus it is tempting to speculate that these findings suggest a difference in the function of Ad-p67dn and gp91ds; i.e., their antiproliferative actions may depend on the particular isoforms and/or subcellular localizations of NADPH oxidase that are affected.
In conclusion, our data are consistent with the involvement of a multicomponent adventitial phagocyte-like NADPH oxidase in neointimal growth. The data indicate that classical p47 phox is critically involved in this response, whereas they appear to suggest only partial involvement of classical p67 phox . However, future studies examining the relative contribution of their homologs, as well as other vascular cells, are necessary. Our findings also shed light on the possible clinical utility of perivascular application of viral inhibitors to reverse deleterious processes involving vascular oxidases.
Perspectives
NADPH oxidases are increasingly being recognized as important mediators in a complex signaling cascade leading to vascular growth. Studies show that the vascular growth response involves c-Src-mediated NADPH oxidase assembly and includes activation of a host of tyrosine and serine/threonine kinases, leading to activation of transcription factors, cell hypertrophy, and proliferation (5, 10, 14, 39) . With the discovery of homologs of the various NADPH oxidase components in the vasculature, including gp91
phox homologs nox1 and nox4, as well as interaction with classical p22 phox (1) and novel cytosolic components (4), clearly the cellular effects of oxidase activation are expected to be multifactorial. Thus a multifaceted, combinatorial pharmacological approach to oxidase inhibition will likely be necessary to attenuate cell growth.
